Clinical Trials Logo

Biliary Tract Tumor clinical trials

View clinical trials related to Biliary Tract Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT06048289 Recruiting - Cholangiocarcinoma Clinical Trials

Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy

Start date: September 14, 2023
Phase:
Study type: Observational

A prospective, observational study to explore multidimensional biomarkers for predicting the efficacy of immunotherapy In biliary tract tumors

NCT ID: NCT05291052 Recruiting - Biliary Tract Tumor Clinical Trials

Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors

Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

This study is a single-center, single-arm, open-label clinical study. All patients with advanced and unresectable biliary tract tumors will be treated with the combination of tisleizumab, lenvatinib and XELOX regimen (oxaliplatin plus capecitabine) until disease progression , unacceptable toxicity, death or the patient meets any other discontinuation criteria described in the protocol, whichever occurs first. Subjects can receive up to 8 cycles of the XELOX regimen. For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years. Patients will be closely monitored for safety and tolerability throughout the study.

NCT ID: NCT04707365 Not yet recruiting - Colorectal Cancer Clinical Trials

Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort

MICADO
Start date: March 2021
Phase: N/A
Study type: Interventional

Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies. Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored. Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers. Method: Retrospective and prospective monocentric cohort study